Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank

Zhang, Xing-Yu; He, Qiangsheng; Jing, Zhong; He, Juan-Xia; Yuan, Jinqiu; Dai, Xiaoyu

doi:10.3389/fphar.2022.949699

Cited by 10 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, 17 full-text articles were screened, and 7 studies were further excluded due to being reviews, not a comparison of interest, and having ineligible study designs. Finally, 10 studies were included in this meta-analysis [ 15 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies

Liao

Kung

et al. 2023

JCM

View full text Add to dashboard Cite

Previous epidemiological studies have raised the concern that the use of proton pump inhibitors (PPIs) is associated with an increased risk of kidney diseases. To date, no comprehensive meta-analysis has been conducted to assess the association between PPIs and the risk of chronic kidney disease (CKD). Therefore, we conducted a systematic review and meta-analysis to address the association between PPIs and CKD. The primary search was conducted in the most popular databases, such as PubMed, Scopus, and Web of Science. All observational studies evaluated the risk of CKD among PPI users, and non-users were considered for inclusion. Two reviewers conducted data extraction and assessed the risk of bias. Random-effect models were used to calculate pooled effect sizes. A total of 6,829,905 participants from 10 observational studies were included. Compared with non-PPI use, PPI use was significantly associated with an increased risk of CKD (RR 1.72, 95% CI: 1.02–2.87, p = 0.03). This updated meta-analysis showed that PPI was significantly associated with an increased risk of CKD. Association was observed in the same among moderate-quality studies. Until further randomized control trials (RCTs) and biological studies confirm these results, PPI therapy should not stop patients with gastroesophageal reflux disease (GERD). However, caution should be used when prescribing to patients with high-risk kidney disease.

show abstract

Section: Resultsmentioning

confidence: 99%

“… Association between PPI use and risk of chronic kidney disease [ 15 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ]. …”

Section: Figurementioning

confidence: 99%

Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies

Liao

Kung

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…The regular use of PPI is associated with a higher risk of CKD. [43] A meta-analysis including 10 observational studies showed that the risk ratio (RR) of CKD associated with PPI use was 1.35 (95% CI: 1.15–1.56) compared to patients without PPIs, p < 0.001. [44] After analysis of several observational and cohort studies, we identified a strong association between PPI use and the occurrence and progression of CKD events.…”

Section: Resultsmentioning

confidence: 99%

Research Progress on the Potential Mechanisms of Acute Kidney Injury and Chronic Kidney Disease Induced by Proton Pump Inhibitors

Song¹,

Gong²

2023

Integr Med Nephrol Androl

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are acid-suppressing medications widely used in peptic ulcers; however, their widespread use has led to many adverse renal events. Among these events, the most common form of acute kidney injury (AKI) is acute interstitial nephritis (AIN), which is the clinical manifestation. Several clinical trials and cohort studies have shown a significant relationship between PPIs and AKI induction; however, the pathogenesis of PPIs leading to AKI is unclear. In this paper, we reviewed the potential mechanisms by which PPIs cause AKI and proposed new conjectures. We considered that PPIs led to the development of AKI through a combination of mechanisms. By searching and reviewing PubMed and Embase, a total of 29 studies were finally included and reviewed, and the findings suggested that the mechanisms by which PPIs induce AKI are mainly related to oxidative stress, immune response, inflammatory response, mitochondrial damage, calcium overload, and the induction of cellular necrosis. In addition, tubular cell necrosis can cause tubulointerstitial fibrosis and progressive renal unit loss. Long-term follow-up observations also suggested that PPIs can contribute to AKI progression to chronic kidney disease (CKD). Therefore, we will also explore the potential link between PPIs and CKD.

show abstract

“…Китайские ученые провели [47] проспективный анализ данных 462 421 участника Британского биобанка и зарегистрировали 7031 случай ХБП за средний период наблюдения 8,1 года. Пациенты, регулярно принимавшие ИПП, имели на 37% более высокий риск развития ХБП, чем те, кто не принимал их (ОР 1,37, 95% ДИ 1,28-1,47).…”

Section: хроническая болезнь почекunclassified

Cardiovascular risk with long-term use of proton pump inhibitors: myth or reality. A review

Trukhan,

Filimonov

2024

Consilium Medicum

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are the most effective drugs for treating acid-related diseases. In recent decades, the use of PPIs has increased exponentially. From gastroenterological practice, PPIs are being actively introduced into other specialties, in particular in cardiology and rheumatology, where they are used to protect the mucous membrane of the gastrointestinal tract and prevent gastrointestinal bleeding during long-term antithrombotic therapy and long-term use of non-steroidal anti-inflammatory drugs. For a long time, PPIs were considered completely safe drugs for both short-term and long-term use. However, modern clinical guidelines note that when prescribing PPIs in large doses for a long period, the possibility of side effects should be taken into account. In recent years, a number of foreign reviews have been published that examine the relationship between PPIs and a number of diseases/conditions, including the question of a possible association of PPI use with an increased risk of cardiovascular complications, but note the inconsistency of these data. We searched the PubMed and Scopus information databases for publications on the safety of PPI use, including sources up to 12/01/2023. In this review, we examined the possible cardiovascular risk of long-term use of PPIs. Analysis of publications, despite a number of contradictions, allows us to conclude that the cardiovascular risk with long-term use of PPIs is real and must be taken into account when prescribing PPIs for a long period and to comorbid/multimorbid patients.

show abstract

Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank

Cited by 10 publications

References 35 publications

Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies

Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies

Research Progress on the Potential Mechanisms of Acute Kidney Injury and Chronic Kidney Disease Induced by Proton Pump Inhibitors

Cardiovascular risk with long-term use of proton pump inhibitors: myth or reality. A review

Contact Info

Product

Resources

About